January 31, 2024
According to a recent Federal Court ruling, PMPRB’s jurisdiction over patented drug prices could also apply to an off-patent drug.
December 13, 2023
The federal government formally announced the creation of the Canadian Drug Agency (CDA), originally identified in the 2019 budget.
November 15, 2023
The PMPRB has posted its Scoping Paper that poses questions to stakeholders to start the first phase of consultations on its new Guidelines.
September 5, 2023
The pCPA Board of Directors recently announced Douglas Clark to be the first CEO of the newly incorporated organization, effective Sept 11.
August 29, 2023
Last week we hosted an incredible session with Canadian Industry Heads! It was great seeing many familiar faces as well as meeting new colleagues. Thank you to everyone that attended, for sharing your perspectives and insights, and contributing to the day’s success.
August 14, 2023
Health Canada has released its updated Guidance on the Distinction Between Advertising and Other Activities.
July 20, 2022
In the period between the coming into force of the new Patented Medicines Regulations and the final publication of a corresponding set of guidelines (“Interim Period”), the PMPRB is proposing to adopt a “status quo” approach to carrying out its regulatory mandate.
July 15, 2022
The Quebec government has released its provincial Rare Disease Policy. This is the first jurisdiction in Canada to develop a policy for rare diseases that aims to help patients suffering from a rare disease gain better access to diagnosis, health care and treatment.
April 25, 2022
The PMPRB has responded to the statement made April 14, 2022, by the Federal Minister
of Health, Minister Duclos regarding the Coming-into-Force of the Regulations Amending
the Patented Medicines Regulations.
March 28, 2022
On March 24, 2022, the Supreme Court of Canada dismissed the application by the Attorney General of Canada in its appeal to the Federal Court Decision in the SOLIRIS case.